Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH) | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Pulmonary Arterial Hypertension (PAH)

A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg

Sub-indication: Pulmonary Arterial Hypertension (PAH)

Study Type: Drug Study

Principal Investigator: John McConnell, M.D.
Norton Pulmonary Specialists

Sponsor: Sponsor: Actelion/Janssen

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Pulmonary Arterial Hypertension (PAH) Clinical Trial

Schedule an Appointment